NCT02050828View on ClinicalTrials.gov

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2015

Conditions
Diabetic Macular Edema (DME)
Interventions
DRUG

AKB-9778

DRUG

ranibizumab

DRUG

Placebo

DRUG

Sham

Trial Locations (39)

14620

Rochester

20186

Warrenton

21287

Baltimore

28210

Charlotte

29501

Florence

33126

Miami

33334

Fort Lauderdale

33426

Boynton Beach

33880

Winter Haven

33912

Fort Myers

34239

Sarasota

34994

Stuart

37203

Nashville

44195

Cleveland

45242

Cincinnati

49202

Jackson

57701

Rapid City

68198

Omaha

76102

Fort Worth

77030

Houston

78240

San Antonio

78503

McAllen

78705

Austin

79606

Abilene

80401

Golden

84107

Salt Lake City

85014

Pheonix

85020

Pheonix

85704

Tucson

89502

Reno

90211

Beverly Hills

91007

Arcadia

92260

Palm Desert

92705

Santa Ana

93103

Santa Barbara

93309

Bakersfield

95819

Sacramento

97210

Portland

98004

Bellevue

Sponsors
All Listed Sponsors
lead

Aerpio Therapeutics

INDUSTRY

NCT02050828 - The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema | Biotech Hunter | Biotech Hunter